With more than 125,000 units internationally and over 7,000 in Australia, Defibtech has drawn accolades for its commitment to save lives by producing the best AEDs medical technology can offer. As an industry leader, Defibtech's commitment to research and innovation consistently pushes them to new levels of excellence.
Defibtech was founded in 1999 by cardiothoracic surgeon Dr. Glenn W. Laub, Professor and Chairman of Cardiac Surgery at Drexel College of Medicine and Clinical Section Chief at Hahnemann University Hospital in Philadelphia, PA, in partnership with his longtime friend and fellow Yale graduate, Gintaras Vaisnys, an engineer and experienced technological entrepreneur.
Their vision: to utilize their extensive experience and talents to build a company that would become a technological leader in the field of AEDs. To that end, the company's focus was and is exclusively AEDs.
Introduced in 2003, the Defibtech AED revolutionized the marketplace. At half the price of other AEDs on the market, it still managed to be a full featured device that conformed to the highest standards of quality and reliability.
Defibtech defibrillators are quality products of the United States, manufactured in state-of-the-art certified facilities.
Defibtech AEDs were chosen to protect the athletes and spectators at the Winter Olympic Games in Torino, Italy, a tribute to their reputation for quality and just one the many honors, distinctions and awards acquired in the few short years since the company's founding.